Bluebird Bio Inc. (NASDAQ:BLUE) was up 3.4% on Thursday . The stock traded as high as $57.71 and last traded at $57.29, with a volume of 431,729 shares. The stock had previously closed at $55.43.

Several equities research analysts recently weighed in on BLUE shares. Maxim Group reaffirmed a “buy” rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Jefferies Group reissued a “positive” rating and set a $80.00 target price on shares of Bluebird Bio in a research note on Thursday, July 14th. BTIG Research reissued a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a research note on Wednesday, June 29th. Vetr downgraded Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 target price for the company. in a research note on Monday, July 4th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $95.00 target price (down previously from $117.00) on shares of Bluebird Bio in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Bluebird Bio has an average rating of “Buy” and an average target price of $92.59.

The stock has a 50-day moving average price of $51.30 and a 200-day moving average price of $46.68. The firm’s market cap is $2.11 billion.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The company earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same quarter last year, the company posted ($1.57) earnings per share. The company’s quarterly revenue was down 68.6% compared to the same quarter last year. On average, equities analysts anticipate that Bluebird Bio Inc. will post ($6.14) earnings per share for the current fiscal year.

In related news, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $40.11, for a total transaction of $40,110.00. Following the transaction, the insider now directly owns 10,600 shares of the company’s stock, valued at approximately $425,166. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Philip D. Gregory sold 2,931 shares of the firm’s stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $39.52, for a total value of $115,833.12. Following the transaction, the insider now directly owns 30,069 shares in the company, valued at $1,188,326.88. The disclosure for this sale can be found here.

Other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares in the last quarter. State of Tennessee Treasury Department boosted its position in shares of Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock worth $30,492,000 after buying an additional 165,303 shares in the last quarter. RS Investment Management Co. LLC boosted its position in shares of Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares in the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.